Academic Frontier
ACS Nano: Quantum dot nano-pharmaceutical preparations significantly improved the pharmacological properties of aging mice, and changed the way of ingestion of metformin and nicotinamide mononucleotid
QQ Academic Group: 1092348845
Detailed
Oral Ag2S quantum dots (QDs) can quickly pass through the small intestine and be absorbed by the liver. Metformin and Nicotinamide Mononucleotide (NMN) target the metabolism and aging process in the liver. Here, Victoria C. Cogger, ANZAC Research Institute, University of Sydney, Australia, and others investigated the pharmacology and toxicology of quantum dot-based nanomedicine as a carrier of metformin and NMN in young and old mice to determine its therapeutic efficacy Whether the reduction effect related to aging can be improved.
Key points of this article:
1) Pharmacokinetic studies have shown that compared with unconjugated preparations, QD-conjugated metformin and NMN have higher bioavailability and selectively accumulate in the liver after oral administration.
2) Pharmacodynamic data shows that compared with unconjugated preparations, QD-conjugated drugs have higher physiological, metabolic and cellular potency (25×metformin; 100×NMN), and highlight the peak induction of glucose tolerance test And greater changes in metabolic response. After two weeks of low-dose QD-NMN (0.8 mg/kg/day) treatment, the glucose tolerance test of young (3 months) mice was improved, while the fasting and fasting of old (18 months and 24 months) mice Feeding insulin levels and insulin resistance improved. High-dose unconjugated NMN (80mg/kg/day) can improve young rats, but has no effect on old rats. After 100 days of administration (320 μg/kg/day), there were no signs of cell necrosis, fibrosis, inflammation or accumulation.
3) Ag2S QD nanomedicine improves the pharmacokinetics and pharmacodynamic properties of metformin and NMN by enhancing the therapeutic efficacy of metformin and NMN, bypassing the classical cellular uptake pathway, and is shown when a single drug is ineffective in aging mice The efficacy of the drug.
references
Nicholas J. Hunt, et al. Quantum Dot Nanomedicine Formulations Dramatically Improve Pharmacological Properties and Alter Uptake Pathways of Metformin and Nicotinamide Mononucleotide in Aging Mice. ACS Nano, 2021.
DOI: 10.1021/acsnano.0c09278
https://doi.org/10.1021/acsnano.0c09278
Key points of this article:
1) Pharmacokinetic studies have shown that compared with unconjugated preparations, QD-conjugated metformin and NMN have higher bioavailability and selectively accumulate in the liver after oral administration.
2) Pharmacodynamic data shows that compared with unconjugated preparations, QD-conjugated drugs have higher physiological, metabolic and cellular potency (25×metformin; 100×NMN), and highlight the peak induction of glucose tolerance test And greater changes in metabolic response. After two weeks of low-dose QD-NMN (0.8 mg/kg/day) treatment, the glucose tolerance test of young (3 months) mice was improved, while the fasting and fasting of old (18 months and 24 months) mice Feeding insulin levels and insulin resistance improved. High-dose unconjugated NMN (80mg/kg/day) can improve young rats, but has no effect on old rats. After 100 days of administration (320 μg/kg/day), there were no signs of cell necrosis, fibrosis, inflammation or accumulation.
3) Ag2S QD nanomedicine improves the pharmacokinetics and pharmacodynamic properties of metformin and NMN by enhancing the therapeutic efficacy of metformin and NMN, bypassing the classical cellular uptake pathway, and is shown when a single drug is ineffective in aging mice The efficacy of the drug.
references
Nicholas J. Hunt, et al. Quantum Dot Nanomedicine Formulations Dramatically Improve Pharmacological Properties and Alter Uptake Pathways of Metformin and Nicotinamide Mononucleotide in Aging Mice. ACS Nano, 2021.
DOI: 10.1021/acsnano.0c09278
https://doi.org/10.1021/acsnano.0c09278
- Previous：
- Next： A Rising 2D Star: Nove
